Internal Medicine
Online ISSN : 1349-7235
Print ISSN : 0918-2918
ISSN-L : 0918-2918
CASE REPORTS
Rituximab Treatment for Adult Patients with Focal Segmental Glomerulosclerosis
Ayami OchiTakashi TakeiKayu NakayamaChihiro IwasakiDaigo KameiYuki TsurutaAri ShimizuShunji ShiohiraTakahito MoriyamaMitsuyo ItabashiToshio MochizukiKeiko UchidaKen TsuchiyaMotoshi HattoriKosaku Nitta
Author information
JOURNAL OPEN ACCESS

2012 Volume 51 Issue 7 Pages 759-762

Details
Abstract

We present two cases with steroid-resistant nephrotic syndrome (SRNS) and two cases with steroid-dependent nephrotic syndrome (SDNS) due to focal segmental glomerulonephritis (FSGS) who were treated with a single dose of rituximab (375 mg/m2). Although the two cases with SRNS showed no response, the two cases with SDNS achieved complete remission. The patients in whom the peripheral B-cell counts subsequently increased after the administration of rituximab demonstrated a relapse. Rituximab may be an effective treatment agent for SDNS with FSGS and the peripheral B-cell count may be a useful marker in such patients for preventing disease relapse.

Content from these authors
© 2012 by The Japanese Society of Internal Medicine
Previous article Next article
feedback
Top